Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: living virus + cancer cells + patients  Related to the article below (Last Update: 5/12/2008)

New Theory Suggests How Hepatitis C May Cause Rare Immune Disease
Science Daily (press release) -
In a way, says Charles, the findings signal good news for patients living with hepatitis C and mixed cryoglobulinemia ? an estimated 100-170 million ...

Economist
Gene therapy Seeing is believing
Economist, UK - May 1, 2008
This variant was able to target selectively cancer cells in humans. Trials on a form of aggressive primary brain tumour have shown one complete regression ...
Living with B
Malaysia Star, Malaysia - Apr 26, 2008
This is a wrong and dangerous assumption as the virus level and the activities of the liver can change over time. It can damage the liver cells, ...
A Plan for Living a Long and Healthy Life (Part 2)
Natural News.com, AZ - May 6, 2008
It also reduced the growth of lung cancer cells and altered the proteins needed for tumors to grow. Research also shows that beta-carotene can change in the ...

Malaysia Star
Crucial for survival
Malaysia Star, Malaysia - May 5, 2008
The shark substance may halt the growth of new blood cells in the retina, which is linked to a loss of retinal function and blindness in these patients. ...
Researcher studies 'molecular scissor'
Times and Transcript, Canada - Apr 28, 2008
One of the basic characteristics of cancer cells is that through mutation, these cells escape our natural immune system and thus are allowed to grow. ...

Natural News.com
A Pomegranate a Day Keeps the Doctor Away
Natural News.com, AZ - May 1, 2008
Drinking eight ounces of the seed-derived juice a day appears to help inhibit cancer of the prostate and inflammatory enzymes in colon cancer cells. ...

The Australian
Miracle man
The Australian, Australia - Apr 30, 2008
Walker says a useful analogy is to think in terms of cells being machine-tool factories, which are then invaded by commandos - the virus - who force the ...

Natural News.com
Rev. Jeremiah Wright is Right about how US Government Uses Blacks ...
Natural News.com, AZ - Apr 29, 2008
Southam tells the patients that they are receiving "some cells," but leaves out the fact that they are cancer cells. He claims he doesn't obtain informed ...
Stanford researchers synthesize compound to flush HIV out of ...
Stanford Report - May 1, 2008
Though antiretroviral "cocktails" can target an active infection, they cannot get at the virus when it retreats inside the host's T cells, where it may lie ...
Full Text Science Magazine (subscription)
all 11 news articles »
Source: Google News

Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases … -
DW Hanto, KJ Gajl-Peczalska, G Frizzera, DC Arthur … - Annals of Surgery, 1983 - pubmedcentral.nih.gov
... Skin cancer in Caucasian renal allograft recipients living in a subtropical ... G. Cellular
localization of an Epstein-Barr virus (EBV)-associated ... Int J Cancer. ...

PHASE I STUDY OF INTRAVESICAL VACCINIA VIRUS AS A VECTOR FOR GENE THERAPY OF BLADDER CANCER -
LG GOMELLA, MJ MASTRANGELO, PA McCUE, HC MAGUIRE, … - The Journal of Urology, 2001 - Elsevier
... 10 6 plaque forming units of living virus in a ... cells seen with the native vaccinia
virus have led ... native vaccinia, an agent in BCG refractory bladder cancer. ...

Visualizing the kinetics of tumor-cell clearance in living animals -
TJ Sweeney, V Mailander, AA Tucker, AB Olomu, W … - Proceedings of the National Academy of Sciences, 1999 - National Acad Sciences
... detection of tumor cells in living animals. ... Developments in cancer therapy have led
to impressive ... target the small numbers of neoplastic cells remaining after ...

… Function and Causes Apoptosis and Radiosensitization in Non-HIV-associated Human Cancer Cells 1 -
F Pajonk, J Himmelsbach, K Riess, A Sommer, WH … - Cancer Research, 2002 - AACR
... for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. ... occupancy
of the human immunodeficiency virus type 1 ... Cancer Res, 5: 2638-2645, 1999 ...

… -GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells -
T Kanda, KF Sullivan, GM Wahl - Curr. Biol, 1998 - actx.current-biology.com
... could directly observe DMs in living cancer cells; DMs often ... domains visualized in
situ in living human cells ... JK Yee, Vesicular stomatitis virus G glycoprotein ...

Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus -
D Liebowitz, D Wang, E Kieff - J Virol, 1986 - pubmedcentral.nih.gov
... Int J Cancer. ... Y, Harada S, Lipscomb H, Krueger G. Epstein-Barr virus as an ...
internalization of insulin and epidermal growth factor on living fibroblastic cells. ...

… for Cross-Species Transmission of Porcine Endogenous Retrovirus in Patients Treated with Living Pig … -
K Paradis, G Langford, Z Long, W Heneine, P … - Science, 1999 - sciencemag.org
... were then tested against the purified whole virus (isolated from a PERV-positive
human 293 cell line ... with no known treatment with living porcine material ...

… to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients -
JS Horoszewicz - US Patent 5,162,504, 1992 - freepatentsonline.com
... promotion agent used by those investigators were Sendai virus and polyethylene ... J.
Cancer 21:2374-281, 1978 ... for binding on the outer surface of living LNCaP cells ...

HUMAN CYTOTOXIC T LYMPHOCYTE RESPONSES TO EPSTEIN-BARR VIRUS INFECTION -
AB Rickinson, DJ Moss - Annual Reviews in Immunology, 1997 - Annual Reviews
... A11 complexes when measured at the surface of living cells, even though ... J. Cancer
24: 402? 6. ... Frequency of multiple Epstein-Barr virus infections from T cell ...

Enhanced Therapeutic Efficacy for Ovarian Cancer with a Serotype 3 Receptor-Targeted Oncolytic … -
A Kanerva, KR Zinn, TR Chaudhuri, JT Lam, K Suzuki … - Molecular Therapy, 2003 - nature.com
... Further, this virus was able to replicate in ovarian cancer primary cell ... in vitro
all viruses present in the supernatant are expected to enter cells. ...

Source: Google Scholar

Living Virus Destroys Cancer Cells In Sarcoma Patients
The Cancer Therapy & Research Center Institute for Drug Development, in collaboration with Oncolytics Biotech Inc., a biotechnology company, has enrolled the first two patients in a new Phase II clinical study for patients with various types of sarcomas that have metastasized to the lung. CTRC is one of only three sites in the United States, and the only in Texas, enrolling patients. The novel anti-cancer therapy, REOLYSIN(R), is a living virus, not a chemotherapy drug, that is toxic to cancer cells but not harmful to normal cells. This novel therapy, using a living virus, is the first of its kind available at CTRC.

According to Monica Mita, MD, principal investigator at the CTRC Institute for Drug Development, REOLYSIN(R)'s name was derived from the human reovirus, a mild virus that occurs naturally in the environment.
"This novel therapy has shown success because the reovirus replicates in and destroys the cancer cells within the patient's body," said Mita. "Cancer cells have several molecular and genetic abnormalities. In normal, healthy cells, the reovirus is unable to reproduce because of an enzyme named PKR. The enzyme is suppressed in cancer cells, and therefore the reovirus can replicate in the cancer cell and kill it."

"REOLYSIN(R) typifies the true targeted therapy approach that seeks to use fundamental differences between cancer and normal cells as the basis for effective anti-cancer approaches and we are thus very excited about the this study," said Francis Giles, MD, director of the CTRC Institute for Drug Development.

Eligible patients are those who have a bone or soft tissue sarcoma that has spread to the lung and who are deemed by their physician to be unresponsive to or untreatable by standard therapies. These include patients with osteosarcoma, Ewing sarcoma family tumors, malignant fibrous histiocytoma, synovial sarcoma, fibrosarcoma and leiomyosarcoma.

The second patient to enroll in the study was diagnosed with breast cancer in April 2005 and 11 months later received an additional diagnosis for a rare form of sarcoma. A specialist at the Dana-Farber Cancer Institute in Boston referred her to CTRC, where Mita suggested the REOLYSIN(R) study. After discussing it with her family and doctor, she decided it was the best treatment option for her.

"This new therapy gives me another option in the fight against my cancer," said the 35-year-old mother of three who travels to San Antonio for treatment with her husband and children. "Before coming to CTRC, I had already been through one chemotherapy cycle for this disease, and I got the impression that no one really knew what to do with me or how to treat my cancer. REOLYSIN(R) was a less toxic option for me."

"We are delighted, but not surprised, with the rate of accrual at the CTRC Institute for Drug Development," said Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. "As an evolving oncology company, the placement of Oncolytics' very innovative and sophisticated studies is of critical importance and we are delighted to have the CTRC Institute for Drug Development as our collaborator. This study is expected to yield information that will guide the late stage clinical development program for REOLYSIN(R)."

REOLYSIN(R) demonstrated success against tumors during earlier phases of scientific testing. This study (REO 014) is a Phase II, open-label, single agent study with the primary objective of measuring tumor responses and the duration of those responses, and of describing any evidence of anti-tumor activity. REOLYSIN(R) will be given intravenously to patients for five consecutive days. Patients may receive additional five-day cycles of therapy every four weeks for a maximum of eight cycles. Up to 52 patients will be enrolled in the study.
Located in San Antonio, Texas, the Cancer Therapy and Research Center (CTRC) is one of the nation's leading academic research and treatment centers, serving more than 4.4 million people in the high-growth corridor of Central and South Texas including Austin, San Antonio, Laredo, and the Rio Grande Valley. CTRC, through its research partnership with the University of Texas Health Science Center at San Antonio (UTHSCSA), created the San Antonio Cancer Institute (SACI), one of a few elite cancer centers in the country to be named a National Cancer Institute (NCI) Designated Cancer Center, and is one of three in Texas. CTRC handles more than 120,000 patient visits each year and is a world leader in developing new drugs to treat cancer. The CTRC Institute for Drug Development (IDD) is internationally recognized for conducting the largest oncology Phase I clinical drug trials program in the world. Sixteen of the cancer drugs most recently approved by the Food & Drug Administration underwent development or testing at the IDD. For more information visit our website at http://www.ctrc.net.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

Cancer Therapy and Research Center
http://www.ctrc.net
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.